Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer - PubMed
4 hours ago
- #obesity and diabetes
- #GLP-1 receptor agonists
- #breast cancer survival
- GLP-1 receptor agonists (GLP-1 RAs) are associated with improved survival and recurrence-free outcomes in breast cancer patients with obesity or type 2 diabetes.
- A retrospective cohort study using TriNetX data from 68 US healthcare organizations analyzed 841,831 breast cancer patients diagnosed between 2006 and 2023.
- Among patients with obesity, GLP-1 RA use was linked to significantly lower all-cause mortality (HR 0.35) and improved recurrence-free survival (HR 0.44) over 10 years.
- In type 2 diabetes patients, GLP-1 RAs compared to insulin or metformin showed lower all-cause mortality (HR 0.09) and better recurrence-free survival (HR 0.33).
- No significant differences were found between GLP-1 RAs and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients.
- Subgroup and landmark analyses supported the main findings, suggesting potential benefits of GLP-1 RAs for breast cancer patients with metabolic comorbidities.